Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 129

Similar articles for PubMed (Select 3793381)

1.

Open label evaluation of cannabidiol in dystonic movement disorders.

Consroe P, Sandyk R, Snider SR.

Int J Neurosci. 1986 Nov;30(4):277-82.

PMID:
3793381
2.

Cannabidiol in dystonic movement disorders.

Sandyk R, Snider SR, Consroe P, Elias SM.

Psychiatry Res. 1986 Jul;18(3):291. No abstract available.

PMID:
3749389
4.

Dystonia in untreated parkinsonism.

LeWitt PA, Burns RS, Newman RP.

Clin Neuropharmacol. 1986;9(3):293-7.

PMID:
3719574
5.

Medical treatment of dystonia.

Pakkenberg H, Pedersen B.

Psychopharmacology Suppl. 1985;2:111-7.

PMID:
2860654
6.
7.

Cannabidiol for the treatment of psychosis in Parkinson's disease.

Zuardi AW, Crippa JA, Hallak JE, Pinto JP, Chagas MH, Rodrigues GG, Dursun SM, Tumas V.

J Psychopharmacol. 2009 Nov;23(8):979-83. doi: 10.1177/0269881108096519. Epub 2008 Sep 18.

PMID:
18801821
8.

Controlled clinical trial of cannabidiol in Huntington's disease.

Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, Schram K.

Pharmacol Biochem Behav. 1991 Nov;40(3):701-8.

PMID:
1839644
9.

[Experience with L-DOPA treatment of children with dystonia musculorum deformans and dystonic hyperkineses in infantile cerebral palsy].

Bondarenko ES, Malyshev IuI.

Zh Nevropatol Psikhiatr Im S S Korsakova. 1985;85(10):1471-5. Russian.

PMID:
4072505
10.

Dystonia-Parkinson syndrome: differential effects of levodopa and dopamine agonists.

Klawans HL, Paleologos N.

Clin Neuropharmacol. 1986;9(3):298-302.

PMID:
3719575
11.

Cannabidiol monotherapy for treatment-resistant schizophrenia.

Zuardi AW, Hallak JE, Dursun SM, Morais SL, Sanches RF, Musty RE, Crippa JA.

J Psychopharmacol. 2006 Sep;20(5):683-6. Epub 2006 Jan 9.

PMID:
16401651
12.

Dopamine agonists in the treatment of dystonia.

Lang AE.

Clin Neuropharmacol. 1985;8(1):38-57. Review. No abstract available.

PMID:
3884150
13.
14.

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.

Wade DT, Robson P, House H, Makela P, Aram J.

Clin Rehabil. 2003 Feb;17(1):21-9.

PMID:
12617376
15.

Involuntary movement disorders.

Still CN.

Neurol Clin. 1984 Feb;2(1):71-89. Review.

PMID:
6239089
16.

A family with hereditary juvenile dystonia-parkinsonism.

Ishikawa A, Miyatake T.

Mov Disord. 1995 Jul;10(4):482-8.

PMID:
7565830
17.

[Diagnostic and therapeutic problems in dystonia musculorum deformans].

Fraioli B, Contratti F, Baldassarre L.

Riv Neurol. 1976 Jan-Feb;46(1):73-80. Italian.

PMID:
796956
18.

Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity.

Dirikoc S, Priola SA, Marella M, Zsürger N, Chabry J.

J Neurosci. 2007 Sep 5;27(36):9537-44.

19.

Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

Russo EB.

Neurology. 2003 Feb 25;60(4):729-30; author reply 729-30. No abstract available.

PMID:
12601130
20.

Parkinsonism following dystonia in three patients.

Katchen M, Duvoisin RC.

Mov Disord. 1986;1(2):151-7.

PMID:
3504239
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk